ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Mammalian CDMO Service Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-10Q17034
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Mammalian CDMO Service Market Research Report 2024
BUY CHAPTERS

Global Mammalian CDMO Service Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-10Q17034
Report
November 2025
Pages:158
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Cytovance Biologics
3P Bio
AGC Biologics
KBI Biopharma
GTP Bioways
Samsung Biologics
Wuxi Biologics
plantform corporation
Gedeon Richter
Lonza
Novartis
Rentschler Biopharma SE
Northway Biotech
Boehringer Ingelheim
Cambrex
FUJIFILM Diosynth Biotechnologies
GBI
Scorpius BioManufacturing
Tanvex CDMO

Mammalian CDMO Service Market

The global Mammalian CDMO Service market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
From a downstream perspective, Contract Research Organizations (CROs) accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Mammalian CDMO Service leading manufacturers including Cytovance Biologics, 3P Bio, AGC Biologics, KBI Biopharma, GTP Bioways, Tanvex CDMO, Samsung Biologics, WuXi Biologics, PlantForm Corporation, Gedeon Richter, etc., dominate supply; the top five capture approximately % of global revenue, with Cytovance Biologics leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Mammalian CDMO Service market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Mammalian CDMO Service Market Report

Report Metric Details
Report Name Mammalian CDMO Service Market
Segment by Type
  • Cell Line Development
  • Genomic Analysis
  • Process Development
  • Analytical Services
  • Formulation Development
  • Manufacturing
  • Others
Segment by Application
  • Contract Research Organizations (CROs)
  • Pharmaceutical
  • Biotechnology Companies
  • Government Agencies
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Cytovance Biologics, 3P Bio, AGC Biologics, KBI Biopharma, GTP Bioways, Tanvex CDMO, Samsung Biologics, WuXi Biologics, PlantForm Corporation, Gedeon Richter, Lonza, Novartis, Rentschler Biopharma SE, Northway Biotech, Boehringer Ingelheim, Cambrex, FUJIFILM Diosynth Biotechnologies, GBI, Scorpius BioManufacturing
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Mammalian CDMO Service study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Mammalian CDMO Service Market report?

Ans: The main players in the Mammalian CDMO Service Market are Cytovance Biologics, 3P Bio, AGC Biologics, KBI Biopharma, GTP Bioways, Tanvex CDMO, Samsung Biologics, WuXi Biologics, PlantForm Corporation, Gedeon Richter, Lonza, Novartis, Rentschler Biopharma SE, Northway Biotech, Boehringer Ingelheim, Cambrex, FUJIFILM Diosynth Biotechnologies, GBI, Scorpius BioManufacturing

What are the Application segmentation covered in the Mammalian CDMO Service Market report?

Ans: The Applications covered in the Mammalian CDMO Service Market report are Contract Research Organizations (CROs), Pharmaceutical, Biotechnology Companies, Government Agencies, Others

What are the Type segmentation covered in the Mammalian CDMO Service Market report?

Ans: The Types covered in the Mammalian CDMO Service Market report are Cell Line Development, Genomic Analysis, Process Development, Analytical Services, Formulation Development, Manufacturing, Others

1 Study Coverage
1.1 Introduction to Mammalian CDMO Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Mammalian CDMO Service Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Cell Line Development
1.2.3 Genomic Analysis
1.2.4 Process Development
1.2.5 Analytical Services
1.2.6 Formulation Development
1.2.7 Manufacturing
1.2.8 Others
1.3 Market Segmentation by Application
1.3.1 Global Mammalian CDMO Service Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Contract Research Organizations (CROs)
1.3.3 Pharmaceutical
1.3.4 Biotechnology Companies
1.3.5 Government Agencies
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Mammalian CDMO Service Revenue Estimates and Forecasts 2020-2031
2.2 Global Mammalian CDMO Service Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Mammalian CDMO Service Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Mammalian CDMO Service Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Cell Line Development Market Size by Players
3.3.2 Genomic Analysis Market Size by Players
3.3.3 Process Development Market Size by Players
3.3.4 Analytical Services Market Size by Players
3.3.5 Formulation Development Market Size by Players
3.3.6 Manufacturing Market Size by Players
3.3.7 Others Market Size by Players
3.4 Global Mammalian CDMO Service Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Mammalian CDMO Service Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Mammalian CDMO Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Mammalian CDMO Service Market Size by Type (2020-2031)
6.4 North America Mammalian CDMO Service Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Mammalian CDMO Service Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Mammalian CDMO Service Market Size by Type (2020-2031)
7.4 Europe Mammalian CDMO Service Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Mammalian CDMO Service Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Mammalian CDMO Service Market Size by Type (2020-2031)
8.4 Asia-Pacific Mammalian CDMO Service Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Mammalian CDMO Service Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Mammalian CDMO Service Market Size by Type (2020-2031)
9.4 Central and South America Mammalian CDMO Service Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Mammalian CDMO Service Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Mammalian CDMO Service Market Size by Type (2020-2031)
10.4 Middle East and Africa Mammalian CDMO Service Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Mammalian CDMO Service Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Cytovance Biologics
11.1.1 Cytovance Biologics Corporation Information
11.1.2 Cytovance Biologics Business Overview
11.1.3 Cytovance Biologics Mammalian CDMO Service Product Features and Attributes
11.1.4 Cytovance Biologics Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.1.5 Cytovance Biologics Mammalian CDMO Service Revenue by Product in 2024
11.1.6 Cytovance Biologics Mammalian CDMO Service Revenue by Application in 2024
11.1.7 Cytovance Biologics Mammalian CDMO Service Revenue by Geographic Area in 2024
11.1.8 Cytovance Biologics Mammalian CDMO Service SWOT Analysis
11.1.9 Cytovance Biologics Recent Developments
11.2 3P Bio
11.2.1 3P Bio Corporation Information
11.2.2 3P Bio Business Overview
11.2.3 3P Bio Mammalian CDMO Service Product Features and Attributes
11.2.4 3P Bio Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.2.5 3P Bio Mammalian CDMO Service Revenue by Product in 2024
11.2.6 3P Bio Mammalian CDMO Service Revenue by Application in 2024
11.2.7 3P Bio Mammalian CDMO Service Revenue by Geographic Area in 2024
11.2.8 3P Bio Mammalian CDMO Service SWOT Analysis
11.2.9 3P Bio Recent Developments
11.3 AGC Biologics
11.3.1 AGC Biologics Corporation Information
11.3.2 AGC Biologics Business Overview
11.3.3 AGC Biologics Mammalian CDMO Service Product Features and Attributes
11.3.4 AGC Biologics Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.3.5 AGC Biologics Mammalian CDMO Service Revenue by Product in 2024
11.3.6 AGC Biologics Mammalian CDMO Service Revenue by Application in 2024
11.3.7 AGC Biologics Mammalian CDMO Service Revenue by Geographic Area in 2024
11.3.8 AGC Biologics Mammalian CDMO Service SWOT Analysis
11.3.9 AGC Biologics Recent Developments
11.4 KBI Biopharma
11.4.1 KBI Biopharma Corporation Information
11.4.2 KBI Biopharma Business Overview
11.4.3 KBI Biopharma Mammalian CDMO Service Product Features and Attributes
11.4.4 KBI Biopharma Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.4.5 KBI Biopharma Mammalian CDMO Service Revenue by Product in 2024
11.4.6 KBI Biopharma Mammalian CDMO Service Revenue by Application in 2024
11.4.7 KBI Biopharma Mammalian CDMO Service Revenue by Geographic Area in 2024
11.4.8 KBI Biopharma Mammalian CDMO Service SWOT Analysis
11.4.9 KBI Biopharma Recent Developments
11.5 GTP Bioways
11.5.1 GTP Bioways Corporation Information
11.5.2 GTP Bioways Business Overview
11.5.3 GTP Bioways Mammalian CDMO Service Product Features and Attributes
11.5.4 GTP Bioways Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.5.5 GTP Bioways Mammalian CDMO Service Revenue by Product in 2024
11.5.6 GTP Bioways Mammalian CDMO Service Revenue by Application in 2024
11.5.7 GTP Bioways Mammalian CDMO Service Revenue by Geographic Area in 2024
11.5.8 GTP Bioways Mammalian CDMO Service SWOT Analysis
11.5.9 GTP Bioways Recent Developments
11.6 Tanvex CDMO
11.6.1 Tanvex CDMO Corporation Information
11.6.2 Tanvex CDMO Business Overview
11.6.3 Tanvex CDMO Mammalian CDMO Service Product Features and Attributes
11.6.4 Tanvex CDMO Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.6.5 Tanvex CDMO Recent Developments
11.7 Samsung Biologics
11.7.1 Samsung Biologics Corporation Information
11.7.2 Samsung Biologics Business Overview
11.7.3 Samsung Biologics Mammalian CDMO Service Product Features and Attributes
11.7.4 Samsung Biologics Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.7.5 Samsung Biologics Recent Developments
11.8 WuXi Biologics
11.8.1 WuXi Biologics Corporation Information
11.8.2 WuXi Biologics Business Overview
11.8.3 WuXi Biologics Mammalian CDMO Service Product Features and Attributes
11.8.4 WuXi Biologics Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.8.5 WuXi Biologics Recent Developments
11.9 PlantForm Corporation
11.9.1 PlantForm Corporation Corporation Information
11.9.2 PlantForm Corporation Business Overview
11.9.3 PlantForm Corporation Mammalian CDMO Service Product Features and Attributes
11.9.4 PlantForm Corporation Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.9.5 PlantForm Corporation Recent Developments
11.10 Gedeon Richter
11.10.1 Gedeon Richter Corporation Information
11.10.2 Gedeon Richter Business Overview
11.10.3 Gedeon Richter Mammalian CDMO Service Product Features and Attributes
11.10.4 Gedeon Richter Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Lonza
11.11.1 Lonza Corporation Information
11.11.2 Lonza Business Overview
11.11.3 Lonza Mammalian CDMO Service Product Features and Attributes
11.11.4 Lonza Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.11.5 Lonza Recent Developments
11.12 Novartis
11.12.1 Novartis Corporation Information
11.12.2 Novartis Business Overview
11.12.3 Novartis Mammalian CDMO Service Product Features and Attributes
11.12.4 Novartis Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.12.5 Novartis Recent Developments
11.13 Rentschler Biopharma SE
11.13.1 Rentschler Biopharma SE Corporation Information
11.13.2 Rentschler Biopharma SE Business Overview
11.13.3 Rentschler Biopharma SE Mammalian CDMO Service Product Features and Attributes
11.13.4 Rentschler Biopharma SE Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.13.5 Rentschler Biopharma SE Recent Developments
11.14 Northway Biotech
11.14.1 Northway Biotech Corporation Information
11.14.2 Northway Biotech Business Overview
11.14.3 Northway Biotech Mammalian CDMO Service Product Features and Attributes
11.14.4 Northway Biotech Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.14.5 Northway Biotech Recent Developments
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Corporation Information
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Mammalian CDMO Service Product Features and Attributes
11.15.4 Boehringer Ingelheim Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.15.5 Boehringer Ingelheim Recent Developments
11.16 Cambrex
11.16.1 Cambrex Corporation Information
11.16.2 Cambrex Business Overview
11.16.3 Cambrex Mammalian CDMO Service Product Features and Attributes
11.16.4 Cambrex Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.16.5 Cambrex Recent Developments
11.17 FUJIFILM Diosynth Biotechnologies
11.17.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.17.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.17.3 FUJIFILM Diosynth Biotechnologies Mammalian CDMO Service Product Features and Attributes
11.17.4 FUJIFILM Diosynth Biotechnologies Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.17.5 FUJIFILM Diosynth Biotechnologies Recent Developments
11.18 GBI
11.18.1 GBI Corporation Information
11.18.2 GBI Business Overview
11.18.3 GBI Mammalian CDMO Service Product Features and Attributes
11.18.4 GBI Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.18.5 GBI Recent Developments
11.19 Scorpius BioManufacturing
11.19.1 Scorpius BioManufacturing Corporation Information
11.19.2 Scorpius BioManufacturing Business Overview
11.19.3 Scorpius BioManufacturing Mammalian CDMO Service Product Features and Attributes
11.19.4 Scorpius BioManufacturing Mammalian CDMO Service Revenue and Gross Margin (2020-2025)
11.19.5 Scorpius BioManufacturing Recent Developments
12 Mammalian CDMO ServiceIndustry Chain Analysis
12.1 Mammalian CDMO Service Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Mammalian CDMO Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Mammalian CDMO Service Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Cytovance Biologics
3P Bio
AGC Biologics
KBI Biopharma
GTP Bioways
Samsung Biologics
Wuxi Biologics
plantform corporation
Gedeon Richter
Lonza
Novartis
Rentschler Biopharma SE
Northway Biotech
Boehringer Ingelheim
Cambrex
FUJIFILM Diosynth Biotechnologies
GBI
Scorpius BioManufacturing
Tanvex CDMO
List of Tables
 Table 1. Global Mammalian CDMO Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Mammalian CDMO Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Mammalian CDMO Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Mammalian CDMO Service Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Mammalian CDMO Service Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Mammalian CDMO Service Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Mammalian CDMO Service Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Mammalian CDMO Service by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mammalian CDMO Service as of 2024)
 Table 11. Global Mammalian CDMO Service Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Mammalian CDMO Service Companies Headquarters
 Table 13. Global Mammalian CDMO Service Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Mammalian CDMO Service Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Mammalian CDMO Service Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Mammalian CDMO Service Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Mammalian CDMO Service Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Mammalian CDMO Service High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Mammalian CDMO Service Growth Accelerators and Market Barriers
 Table 25. North America Mammalian CDMO Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Mammalian CDMO Service Growth Accelerators and Market Barriers
 Table 27. Europe Mammalian CDMO Service Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Mammalian CDMO Service Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Mammalian CDMO Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Mammalian CDMO Service Investment Opportunities and Key Challenges
 Table 31. Central and South America Mammalian CDMO Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Mammalian CDMO Service Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Mammalian CDMO Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Cytovance Biologics Corporation Information
 Table 35. Cytovance Biologics Description and Major Businesses
 Table 36. Cytovance Biologics Product Features and Attributes
 Table 37. Cytovance Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Cytovance Biologics Revenue Proportion by Product in 2024
 Table 39. Cytovance Biologics Revenue Proportion by Application in 2024
 Table 40. Cytovance Biologics Revenue Proportion by Geographic Area in 2024
 Table 41. Cytovance Biologics Mammalian CDMO Service SWOT Analysis
 Table 42. Cytovance Biologics Recent Developments
 Table 43. 3P Bio Corporation Information
 Table 44. 3P Bio Description and Major Businesses
 Table 45. 3P Bio Product Features and Attributes
 Table 46. 3P Bio Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. 3P Bio Revenue Proportion by Product in 2024
 Table 48. 3P Bio Revenue Proportion by Application in 2024
 Table 49. 3P Bio Revenue Proportion by Geographic Area in 2024
 Table 50. 3P Bio Mammalian CDMO Service SWOT Analysis
 Table 51. 3P Bio Recent Developments
 Table 52. AGC Biologics Corporation Information
 Table 53. AGC Biologics Description and Major Businesses
 Table 54. AGC Biologics Product Features and Attributes
 Table 55. AGC Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. AGC Biologics Revenue Proportion by Product in 2024
 Table 57. AGC Biologics Revenue Proportion by Application in 2024
 Table 58. AGC Biologics Revenue Proportion by Geographic Area in 2024
 Table 59. AGC Biologics Mammalian CDMO Service SWOT Analysis
 Table 60. AGC Biologics Recent Developments
 Table 61. KBI Biopharma Corporation Information
 Table 62. KBI Biopharma Description and Major Businesses
 Table 63. KBI Biopharma Product Features and Attributes
 Table 64. KBI Biopharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. KBI Biopharma Revenue Proportion by Product in 2024
 Table 66. KBI Biopharma Revenue Proportion by Application in 2024
 Table 67. KBI Biopharma Revenue Proportion by Geographic Area in 2024
 Table 68. KBI Biopharma Mammalian CDMO Service SWOT Analysis
 Table 69. KBI Biopharma Recent Developments
 Table 70. GTP Bioways Corporation Information
 Table 71. GTP Bioways Description and Major Businesses
 Table 72. GTP Bioways Product Features and Attributes
 Table 73. GTP Bioways Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. GTP Bioways Revenue Proportion by Product in 2024
 Table 75. GTP Bioways Revenue Proportion by Application in 2024
 Table 76. GTP Bioways Revenue Proportion by Geographic Area in 2024
 Table 77. GTP Bioways Mammalian CDMO Service SWOT Analysis
 Table 78. GTP Bioways Recent Developments
 Table 79. Tanvex CDMO Corporation Information
 Table 80. Tanvex CDMO Description and Major Businesses
 Table 81. Tanvex CDMO Product Features and Attributes
 Table 82. Tanvex CDMO Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Tanvex CDMO Recent Developments
 Table 84. Samsung Biologics Corporation Information
 Table 85. Samsung Biologics Description and Major Businesses
 Table 86. Samsung Biologics Product Features and Attributes
 Table 87. Samsung Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Samsung Biologics Recent Developments
 Table 89. WuXi Biologics Corporation Information
 Table 90. WuXi Biologics Description and Major Businesses
 Table 91. WuXi Biologics Product Features and Attributes
 Table 92. WuXi Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. WuXi Biologics Recent Developments
 Table 94. PlantForm Corporation Corporation Information
 Table 95. PlantForm Corporation Description and Major Businesses
 Table 96. PlantForm Corporation Product Features and Attributes
 Table 97. PlantForm Corporation Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. PlantForm Corporation Recent Developments
 Table 99. Gedeon Richter Corporation Information
 Table 100. Gedeon Richter Description and Major Businesses
 Table 101. Gedeon Richter Product Features and Attributes
 Table 102. Gedeon Richter Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Gedeon Richter Recent Developments
 Table 104. Lonza Corporation Information
 Table 105. Lonza Description and Major Businesses
 Table 106. Lonza Product Features and Attributes
 Table 107. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Lonza Recent Developments
 Table 109. Novartis Corporation Information
 Table 110. Novartis Description and Major Businesses
 Table 111. Novartis Product Features and Attributes
 Table 112. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. Novartis Recent Developments
 Table 114. Rentschler Biopharma SE Corporation Information
 Table 115. Rentschler Biopharma SE Description and Major Businesses
 Table 116. Rentschler Biopharma SE Product Features and Attributes
 Table 117. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. Rentschler Biopharma SE Recent Developments
 Table 119. Northway Biotech Corporation Information
 Table 120. Northway Biotech Description and Major Businesses
 Table 121. Northway Biotech Product Features and Attributes
 Table 122. Northway Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 123. Northway Biotech Recent Developments
 Table 124. Boehringer Ingelheim Corporation Information
 Table 125. Boehringer Ingelheim Description and Major Businesses
 Table 126. Boehringer Ingelheim Product Features and Attributes
 Table 127. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 128. Boehringer Ingelheim Recent Developments
 Table 129. Cambrex Corporation Information
 Table 130. Cambrex Description and Major Businesses
 Table 131. Cambrex Product Features and Attributes
 Table 132. Cambrex Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 133. Cambrex Recent Developments
 Table 134. FUJIFILM Diosynth Biotechnologies Corporation Information
 Table 135. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
 Table 136. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
 Table 137. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 138. FUJIFILM Diosynth Biotechnologies Recent Developments
 Table 139. GBI Corporation Information
 Table 140. GBI Description and Major Businesses
 Table 141. GBI Product Features and Attributes
 Table 142. GBI Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 143. GBI Recent Developments
 Table 144. Scorpius BioManufacturing Corporation Information
 Table 145. Scorpius BioManufacturing Description and Major Businesses
 Table 146. Scorpius BioManufacturing Product Features and Attributes
 Table 147. Scorpius BioManufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 148. Scorpius BioManufacturing Recent Developments
 Table 149. Raw Materials Key Suppliers
 Table 150. Distributors List
 Table 151. Market Trends and Market Evolution
 Table 152. Market Drivers and Opportunities
 Table 153. Market Challenges, Risks, and Restraints
 Table 154. Research Programs/Design for This Report
 Table 155. Key Data Information from Secondary Sources
 Table 156. Key Data Information from Primary Sources


List of Figures
 Figure 1. Mammalian CDMO Service Product Picture
 Figure 2. Global Mammalian CDMO Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Cell Line Development Product Picture
 Figure 4. Genomic Analysis Product Picture
 Figure 5. Process Development Product Picture
 Figure 6. Analytical Services Product Picture
 Figure 7. Formulation Development Product Picture
 Figure 8. Manufacturing Product Picture
 Figure 9. Others Product Picture
 Figure 10. Global Mammalian CDMO Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 11. Contract Research Organizations (CROs)
 Figure 12. Pharmaceutical
 Figure 13. Biotechnology Companies
 Figure 14. Government Agencies
 Figure 15. Others
 Figure 16. Mammalian CDMO Service Report Years Considered
 Figure 17. Global Mammalian CDMO Service Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 19. Global Mammalian CDMO Service Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 20. Global Mammalian CDMO Service Revenue Market Share by Region (2020-2031)
 Figure 21. Global Mammalian CDMO Service Revenue Market Share Ranking (2024)
 Figure 22. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 23. Cell Line Development Revenue Market Share by Player in 2024
 Figure 24. Genomic Analysis Revenue Market Share by Player in 2024
 Figure 25. Process Development Revenue Market Share by Player in 2024
 Figure 26. Analytical Services Revenue Market Share by Player in 2024
 Figure 27. Formulation Development Revenue Market Share by Player in 2024
 Figure 28. Manufacturing Revenue Market Share by Player in 2024
 Figure 29. Others Revenue Market Share by Player in 2024
 Figure 30. Global Mammalian CDMO Service Revenue Market Share by Type (2020-2031)
 Figure 31. Global Mammalian CDMO Service Revenue Market Share by Application (2020-2031)
 Figure 32. North America Mammalian CDMO Service Revenue YoY (2020-2031) & (US$ Million)
 Figure 33. North America Top 5 Players Mammalian CDMO Service Revenue (US$ Million) in 2024
 Figure 34. North America Mammalian CDMO Service Revenue (US$ Million) by Type (2020 - 2031)
 Figure 35. North America Mammalian CDMO Service Revenue (US$ Million) by Application (2020-2031)
 Figure 36. US Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 37. Canada Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 38. Mexico Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 39. Europe Mammalian CDMO Service Revenue YoY (2020-2031) & (US$ Million)
 Figure 40. Europe Top 5 Players Mammalian CDMO Service Revenue (US$ Million) in 2024
 Figure 41. Europe Mammalian CDMO Service Revenue (US$ Million) by Type (2020-2031)
 Figure 42. Europe Mammalian CDMO Service Revenue (US$ Million) by Application (2020-2031)
 Figure 43. Germany Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 44. France Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 45. U.K. Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 46. Italy Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 47. Russia Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 48. Asia-Pacific Mammalian CDMO Service Revenue YoY (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific Top 8 Players Mammalian CDMO Service Revenue (US$ Million) in 2024
 Figure 50. Asia-Pacific Mammalian CDMO Service Revenue (US$ Million) by Type (2020-2031)
 Figure 51. Asia-Pacific Mammalian CDMO Service Revenue (US$ Million) by Application (2020-2031)
 Figure 52. Indonesia Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 53. Japan Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 54. South Korea Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 55. Australia Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 56. India Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 57. Indonesia Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 58. Vietnam Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 59. Malaysia Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 60. Philippines Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 61. Singapore Mammalian CDMO Service Revenue (2020-2031) & (US$ Million)
 Figure 62. Central and South America Mammalian CDMO Service Revenue YoY (2020-2031) & (US$ Million)
 Figure 63. Central and South America Top 5 Players Mammalian CDMO Service Revenue (US$ Million) in 2024
 Figure 64. Central and South America Mammalian CDMO Service Revenue (US$ Million) by Type (2020-2031)
 Figure 65. Central and South America Mammalian CDMO Service Revenue (US$ Million) by Application (2020-2031)
 Figure 66. Brazil Mammalian CDMO Service Revenue (2020-2025) & (US$ Million)
 Figure 67. Argentina Mammalian CDMO Service Revenue (2020-2025) & (US$ Million)
 Figure 68. Middle East and Africa Mammalian CDMO Service Revenue YoY (2020-2031) & (US$ Million)
 Figure 69. Middle East and Africa Top 5 Players Mammalian CDMO Service Revenue (US$ Million) in 2024
 Figure 70. South America Mammalian CDMO Service Revenue (US$ Million) by Type (2020-2031)
 Figure 71. Middle East and Africa Mammalian CDMO Service Revenue (US$ Million) by Application (2020-2031)
 Figure 72. GCC Countries Mammalian CDMO Service Revenue (2020-2025) & (US$ Million)
 Figure 73. Israel Mammalian CDMO Service Revenue (2020-2025) & (US$ Million)
 Figure 74. Egypt Mammalian CDMO Service Revenue (2020-2025) & (US$ Million)
 Figure 75. South Africa Mammalian CDMO Service Revenue (2020-2025) & (US$ Million)
 Figure 76. Mammalian CDMO Service Industry Chain Mapping
 Figure 77. Channels of Distribution (Direct Vs Distribution)
 Figure 78. Bottom-up and Top-down Approaches for This Report
 Figure 79. Data Triangulation
 Figure 80. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Medical Device CDMO Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Microbial CDMO Service Market Research Report 2024
Global Cell Therapy CDMO Market Research Report 2025
Global Plasmid CDMO Services Market Research Report 2025
Global Cell and Gene Therapy CDMO Market Research Report 2024
Global Innovative Drug CDMO Market Research Report 2024
Global Biologics Clinical Manufacturing CDMO Service Market Research Report 2024
Global Small Molecule Innovator CDMO Market Research Report 2025
Global Gene Cell Therapy CDMO Market Research Report 2024
Intermediate CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pharmaceutical Intermediate CDMO Market Research Report 2024
Global CMO and CDMO biotechnology Market Research Report 2024
Global Medical Device CDMO and CRO Market Research Report 2025
Global Exosome CDMO Market Research Report 2024
Global Chemical API CDMO Market Research Report 2024
Small Molecule CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antibody and Recombinant Protein CDMO Market Research Report 2025
Packaging CDMO Market
Softgel CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Plasmid DNA CDMO Market
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions